Tag: neuropathy

Studies

• Promising Roles of Phytocompounds and Nutrients in Interventions to Mitigate Chemotherapy-Induced Peripheral Neuropathy Cite
  Daniel M, Smith EL. Promising Roles of Phytocompounds and Nutrients in Interventions to Mitigate Chemotherapy-Induced Peripheral Neuropathy. Seminars in Oncology Nursing. Elsevier BV; 2024;:151713 10.1016/j.soncn.2024.151713
• Impact of exercise on chemotherapy-induced peripheral neuropathy in survivors with post-treatment primary breast cancer Cite
  Saint K, Nemirovsky D, Lessing A, Chen Y, Yang M, Underwood WP, et al. Impact of exercise on chemotherapy-induced peripheral neuropathy in survivors with post-treatment primary breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2024; 10.1007/s10549-024-07342-6
• Gut microbiome in association with chemotherapy‐induced toxicities among patients with breast cancer Cite
  Nguyen SM, Tran HTT, Long J, Shrubsole MJ, Cai H, Yang Y, et al. Gut microbiome in association with chemotherapy‐induced toxicities among patients with breast cancer. Cancer. Wiley; 2024; 10.1002/cncr.35229
• Electroacupuncture use for treatment of taxane-induced peripheral neuropathy in patients with breast cancer: protocol for a pilot, randomised, blinded, sham-controlled trial (EA for CIPN) Cite
  Choi V, Park SB, Lacey J, Kumar S, Heller G, Grimison P. Electroacupuncture use for treatment of taxane-induced peripheral neuropathy in patients with breast cancer: protocol for a pilot, randomised, blinded, sham-controlled trial (EA for CIPN). BMJ Open. BMJ; 2024; 14:e076391 10.1136/bmjopen-2023-076391
• Voluntary wheel running prevents formation of membrane attack complexes and myelin degradation after peripheral nerve injury Cite
  Green-Fulgham SM, Lacagnina MJ, Willcox KF, Li J, Harland ME, Ciena AP, et al. Voluntary wheel running prevents formation of membrane attack complexes and myelin degradation after peripheral nerve injury. Brain, Behavior, and Immunity. Elsevier BV; 2024; 115:419-431 10.1016/j.bbi.2023.10.027
• Vitamin D Insufficiency as a Risk Factor for Paclitaxel-Induced Peripheral Neuropathy in SWOG S0221 Cite
  Chen C, Zirpoli G, Barlow WE, Budd GT, McKiver B, Pusztai L, et al. Vitamin D Insufficiency as a Risk Factor for Paclitaxel-Induced Peripheral Neuropathy in SWOG S0221. Journal of the National Comprehensive Cancer Network. Harborside Press, LLC; 2023; 21:1172-1180.e3 10.6004/jnccn.2023.7062
• Efficacy of metformin in prevention of paclitaxel-induced peripheral neuropathy in breast cancer patients: a randomized controlled trial Cite
  Bakry HM, Mansour NO, ElKhodary TR, Soliman MM. Efficacy of metformin in prevention of paclitaxel-induced peripheral neuropathy in breast cancer patients: a randomized controlled trial. Frontiers in Pharmacology. Frontiers Media SA; 2023; 14 10.3389/fphar.2023.1181312
• Omega-3 fatty acids as adjuvant therapy in the adverse effects of antineoplastic treatment for breast cancer: a systematic review Cite
  Delmicon NE, Brandão-Lima PN, Rogero MM, Miranda MLP. Omega-3 fatty acids as adjuvant therapy in the adverse effects of antineoplastic treatment for breast cancer: a systematic review. Nutrire. Springer Science and Business Media LLC; 2023; 48 10.1186/s41110-023-00231-w
• Chemotherapy induced peripheral neuropathy (CIPN) due to paclitaxel versus docetaxel in patients with early-stage breast cancer receiving taxane therapy: SWOG S1714. Cite
  Trivedi MS, Unger JM, Hershman DL, Darke A, Hertz DL, Brannagan T, et al. Chemotherapy induced peripheral neuropathy (CIPN) due to paclitaxel versus docetaxel in patients with early-stage breast cancer receiving taxane therapy: SWOG S1714.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2023; 41:12003-12003 10.1200/jco.2023.41.16_suppl.12003
• Safety and efficacy of vitamin B in cancer treatments: A systematic review Cite
  Van de Roovaart HJ, Stevens MM, Goodridge AE, Baden KR, Sibbitt BG, Delaney E, et al. Safety and efficacy of vitamin B in cancer treatments: A systematic review. Journal of Oncology Pharmacy Practice. SAGE Publications; 2023;:107815522311786 10.1177/10781552231178686
• Safety and efficacy of cannabidiol in the management of chemotherapy-induced peripheral neuropathy. Cite
  Weiss MC, Giaddui M, Kjelstrom S, Erebor E, Meske S, Saeed L, et al. Safety and efficacy of cannabidiol in the management of chemotherapy-induced peripheral neuropathy.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2023; 41:12020-12020 10.1200/jco.2023.41.16_suppl.12020
• Role of alpha-lipoic acid in counteracting paclitaxel- and doxorubicin-induced toxicities: a randomized controlled trial in breast cancer patients Cite
  Werida RH, Elshafiey RA, Ghoneim A, Elzawawy S, Mostafa TM. Role of alpha-lipoic acid in counteracting paclitaxel- and doxorubicin-induced toxicities: a randomized controlled trial in breast cancer patients. Supportive Care in Cancer. Springer Science and Business Media LLC; 2022; 10.1007/s00520-022-07124-0
• The effect of trastuzumab on taxane-induced peripheral neuropathy in women with breast cancer: a population-based cohort study Cite
  Patel R, Lyne-Ethier J, Brogly S, Griffiths R, Hendry JM. The effect of trastuzumab on taxane-induced peripheral neuropathy in women with breast cancer: a population-based cohort study. Research Square Platform LLC; 2022; 10.21203/rs.3.rs-1254626/v1
• Beneficial effects of exercise on chemotherapy-induced peripheral neuropathy and sleep disturbance: A review of literature and proposed mechanisms Cite
  Brett Whalen L, Zachary Wright W, Kundur P, Angadi S, Modesitt SC. Beneficial effects of exercise on chemotherapy-induced peripheral neuropathy and sleep disturbance: A review of literature and proposed mechanisms. Gynecologic Oncology Reports. Elsevier BV; 2022; 39:100927 10.1016/j.gore.2022.100927
• The protective effects of hesperidin against paclitaxel-induced peripheral neuropathy in rats Cite
  Semis HS, Kandemir FM, Kaynar O, Dogan T, Arikan SM. The protective effects of hesperidin against paclitaxel-induced peripheral neuropathy in rats. Life Sciences. Elsevier BV; 2021; 287:120104 10.1016/j.lfs.2021.120104
• Chemotherapy-Induced Peripheral Neuropathy: Epidemiology, Pathomechanisms and Treatment Cite
  Burgess J, Ferdousi M, Gosal D, Boon C, Matsumoto K, Marshall A, et al. Chemotherapy-Induced Peripheral Neuropathy: Epidemiology, Pathomechanisms and Treatment. Oncology and Therapy. Springer Science and Business Media LLC; 2021; 10.1007/s40487-021-00168-y
• Occurrence and perceived effectiveness of activities used to decrease chemotherapy-induced peripheral neuropathy symptoms in the feet Cite
  Ogle T, Alexander K, Yates P, Paul SM, Kober KM, Conley YP, et al. Occurrence and perceived effectiveness of activities used to decrease chemotherapy-induced peripheral neuropathy symptoms in the feet. European Journal of Oncology Nursing. Elsevier BV; 2021; 54:102025 10.1016/j.ejon.2021.102025
• Prevalence and predictors of peripheral neuropathy after breast cancer treatment Cite
  Kamgar M, Greenwald MK, Assad H, Hastert TA, McLaughlin EM, Reding KW, et al. Prevalence and predictors of peripheral neuropathy after breast cancer treatment. Cancer Medicine. Wiley; 2021; 10.1002/cam4.4202
• Persistent taxane‐induced neuropathy in elderly patients treated for localized breast cancer Cite
  Pabst L, Velten M, Fischbach C, Kalish M, Pflumio C, Pivot X, et al. Persistent taxane‐induced neuropathy in elderly patients treated for localized breast cancer. The Breast Journal. Wiley; 2020; 26:2376-2382 10.1111/tbj.14123
• Impact of Exercise on Chemotherapy Tolerance and Survival in Early-Stage Breast Cancer: A Nonrandomized Controlled Trial Cite
  Kirkham AA, Gelmon KA, Van Patten CL, Bland KA, Wollmann H, McKenzie DC, et al. Impact of Exercise on Chemotherapy Tolerance and Survival in Early-Stage Breast Cancer: A Nonrandomized Controlled Trial. Journal of the National Comprehensive Cancer Network. Harborside Press, LLC; 2020; 18:1670-1677 10.6004/jnccn.2020.7603
• Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update Cite
  Loprinzi CL, Lacchetti C, Bleeker J, Cavaletti G, Chauhan C, Hertz DL, et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2020; 38:3325-3348 10.1200/jco.20.01399
• Paclitaxel-induced peripheral neuropathy in early-stage breast cancer patients. Cite
  Liu J, Sorooshian H. Paclitaxel-induced peripheral neuropathy in early-stage breast cancer patients.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2020; 38:e12503-e12503 10.1200/jco.2020.38.15_suppl.e12503
• Vitamin D deficiency increases severity of paclitaxel-induced peripheral neuropathy Cite
  Jennaro TS, Fang F, Kidwell KM, Smith EML, Vangipuram K, Burness ML, et al. Vitamin D deficiency increases severity of paclitaxel-induced peripheral neuropathy. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 180:707-714 10.1007/s10549-020-05584-8
• Risk of incident claims for chemotherapy-induced peripheral neuropathy among women with breast cancer in a Medicare population Cite
  Greenwald MK, Ruterbusch JJ, Beebe-Dimmer JL, Simon MS, Albrecht TL, Schwartz AG. Risk of incident claims for chemotherapy-induced peripheral neuropathy among women with breast cancer in a Medicare population. Cancer. Wiley; 2018; 125:269-277 10.1002/cncr.31798
• Associations between self-reported diet during treatment and chemotherapy-induced peripheral neuropathy in a cooperative group trial (S0221) Cite
  Mongiovi JM, Zirpoli GR, Cannioto R, Sucheston-Campbell LE, Hershman DL, Unger JM, et al. Associations between self-reported diet during treatment and chemotherapy-induced peripheral neuropathy in a cooperative group trial (S0221). Breast Cancer Research. Springer Science and Business Media LLC; 2018; 20 10.1186/s13058-018-1077-9
• Risk factors for paclitaxel-induced peripheral neuropathy in patients with breast cancer Cite
  Ghoreishi Z, Keshavarz S, Asghari Jafarabadi M, Fathifar Z, Goodman KA, Esfahani A. Risk factors for paclitaxel-induced peripheral neuropathy in patients with breast cancer. BMC Cancer. Springer Science and Business Media LLC; 2018; 18 10.1186/s12885-018-4869-5
• Chronic Pain in Breast Cancer Survivors: Nociceptive, Neuropathic, or Central Sensitization Pain? Cite
  Leysen L, Adriaenssens N, Nijs J, Pas R, Bilterys T, Vermeir S, et al. Chronic Pain in Breast Cancer Survivors: Nociceptive, Neuropathic, or Central Sensitization Pain?. Pain Practice. Wiley; 2018; 19:183-195 10.1111/papr.12732
• A phase IIA trial of acupuncture to reduce chemotherapy-induced peripheral neuropathy severity during neoadjuvant or adjuvant weekly paclitaxel chemotherapy in breast cancer patients Cite
  Bao T, Seidman AD, Piulson L, Vertosick E, Chen X, Vickers AJ, et al. A phase IIA trial of acupuncture to reduce chemotherapy-induced peripheral neuropathy severity during neoadjuvant or adjuvant weekly paclitaxel chemotherapy in breast cancer patients. European Journal of Cancer. Elsevier BV; 2018; 101:12-19 10.1016/j.ejca.2018.06.008
• Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial Cite
  Kleckner IR, Kamen C, Gewandter JS, Mohile NA, Heckler CE, Culakova E, et al. Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial. Supportive Care in Cancer. Springer Science and Business Media LLC; 2017; 26:1019-1028 10.1007/s00520-017-4013-0
• Effects of Cryotherapy on Objective and Subjective Symptoms of Paclitaxel-Induced Neuropathy: Prospective Self-Controlled Trial Cite
  Hanai A, Ishiguro H, Sozu T, Tsuda M, Yano I, Nakagawa T, et al. Effects of Cryotherapy on Objective and Subjective Symptoms of Paclitaxel-Induced Neuropathy: Prospective Self-Controlled Trial. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2017; 110:141-148 10.1093/jnci/djx178
• Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30 Cite
  Bandos H, Melnikow J, Rivera DR, Swain SM, Sturtz K, Fehrenbacher L, et al. Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2017; 110 10.1093/jnci/djx162
• Persistent impairments 3 years after (neo)adjuvant chemotherapy for breast cancer: results from the MaTox project Cite
  Hurtz H, Tesch H, Göhler T, Hutzschenreuter U, Harde J, Kruggel L, et al. Persistent impairments 3 years after (neo)adjuvant chemotherapy for breast cancer: results from the MaTox project. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2017; 165:721-731 10.1007/s10549-017-4365-7
• Two-year trends of taxane-induced neuropathy in women enrolled in a randomized trial of acetyl-l-carnitine (SWOG S0715). Cite
  Hershman DL, Unger JM, Crew KD, Ebnesajjad C, Greenlee H, Fehrenbacher L, et al. Two-year trends of taxane-induced neuropathy in women enrolled in a randomized trial of acetyl-l-carnitine (SWOG S0715).. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2017; 35:10093-10093 10.1200/jco.2017.35.15_suppl.10093
• Gait, balance, and patient-reported outcomes during taxane-based chemotherapy in early-stage breast cancer patients Cite
  Monfort SM, Pan X, Patrick R, Ramaswamy B, Wesolowski R, Naughton MJ, et al. Gait, balance, and patient-reported outcomes during taxane-based chemotherapy in early-stage breast cancer patients. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2017; 164:69-77 10.1007/s10549-017-4230-8
• Chemotherapy-induced-peripheral neuropathy, gait and fall risk in older adults following cancer treatment Cite
  Marshall TF, Zipp GP, Battaglia F, Moss R, Bryan S. Chemotherapy-induced-peripheral neuropathy, gait and fall risk in older adults following cancer treatment. Journal of Cancer Research and Practice. Medknow; 2017; 4:134-138 10.1016/j.jcrpr.2017.03.005
• Nicotinamide riboside, a form of vitamin B3 and NAD+ precursor, relieves the nociceptive and aversive dimensions of paclitaxel-induced peripheral neuropathy in female rats Cite
  Hamity MV, White SR, Walder RY, Schmidt MS, Brenner C, Hammond DL. Nicotinamide riboside, a form of vitamin B3 and NAD+ precursor, relieves the nociceptive and aversive dimensions of paclitaxel-induced peripheral neuropathy in female rats. PAIN. Ovid Technologies (Wolters Kluwer Health); 2017; 158:962-972 10.1097/j.pain.0000000000000862
• Effects of paclitaxel on the development of neuropathy and affective behaviors in the mouse Cite
  Toma W, Kyte SL, Bagdas D, Alkhlaif Y, Alsharari SD, Lichtman AH, et al. Effects of paclitaxel on the development of neuropathy and affective behaviors in the mouse. Neuropharmacology. Elsevier BV; 2017; 117:305-315 10.1016/j.neuropharm.2017.02.020
• Use of an alpha lipoic, methylsulfonylmethane and bromelain dietary supplement (Opera®) for chemotherapy-induced peripheral neuropathy management, a prospective study Cite
  Desideri I, Francolini G, Becherini C, Terziani F, Delli Paoli C, Olmetto E, et al. Use of an alpha lipoic, methylsulfonylmethane and bromelain dietary supplement (Opera®) for chemotherapy-induced peripheral neuropathy management, a prospective study. Medical Oncology. Springer Science and Business Media LLC; 2017; 34 10.1007/s12032-017-0907-4
• Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)–Positive Metastatic Breast Cancer Cite
  Rugo HS, Barve A, Waller CF, Hernandez-Bronchud M, Herson J, Yuan J, et al. Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)–Positive Metastatic Breast Cancer. JAMA. American Medical Association (AMA); 2017; 317:37 10.1001/jama.2016.18305
• Cancer-related fatigue in breast cancer survivors: more evidence for a physiological substrate Cite
  Ramos J, Cantos B, Maximiano C, Cebolla H, Fiuza-Luces C, Gutierrez L, et al. Cancer-related fatigue in breast cancer survivors: more evidence for a physiological substrate. Annals of Oncology. Elsevier BV; 2016; 27:vi518 10.1093/annonc/mdw390.64
• BMI, Lifestyle Factors and Taxane-Induced Neuropathy in Breast Cancer Patients: The Pathways Study Cite
  Greenlee H, Hershman DL, Shi Z, Kwan ML, Ergas IJ, Roh JM, et al. BMI, Lifestyle Factors and Taxane-Induced Neuropathy in Breast Cancer Patients: The Pathways Study. Journal of the National Cancer Institute. Oxford University Press (OUP); 2016; 109:djw206 10.1093/jnci/djw206
• A randomised, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing the development of chemotherapy-induced peripheral neuropathy (CIPN) Cite
  Schloss JM, Colosimo M, Airey C, Masci P, Linnane AW, Vitetta L. A randomised, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing the development of chemotherapy-induced peripheral neuropathy (CIPN). Supportive Care in Cancer. Springer Science and Business Media LLC; 2016; 25:195-204 10.1007/s00520-016-3404-y
• Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk Cite
  Bao T, Basal C, Seluzicki C, Li SQ, Seidman AD, Mao JJ. Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2016; 159:327-333 10.1007/s10549-016-3939-0
• Abstract 3413: Supplement use and chemotherapy-induced peripheral neuropathy in breast cancer patients treated on SWOG study S0221 Cite
  Zirpoli GR, McCann SE, Sucheston-Campbell LE, Hershman DL, Ciupak G, Davis W, et al. Abstract 3413: Supplement use and chemotherapy-induced peripheral neuropathy in breast cancer patients treated on SWOG study S0221. Epidemiology. American Association for Cancer Research; 2016; 10.1158/1538-7445.am2016-3413
• Chemotherapy-induced peripheral neuropathy: an update on the current understanding Cite
  Addington J, Freimer M. Chemotherapy-induced peripheral neuropathy: an update on the current understanding. F1000Research. F1000 Research Ltd; 2016; 5:1466 10.12688/f1000research.8053.1
• Taxane induced neuropathy in patients affected by breast cancer: Literature review Cite
  De Iuliis F, Taglieri L, Salerno G, Lanza R, Scarpa S. Taxane induced neuropathy in patients affected by breast cancer: Literature review. Critical Reviews in Oncology/Hematology. Elsevier BV; 2015; 96:34-45 10.1016/j.critrevonc.2015.04.011
• Clinical Practice Guidelines on the Use of Integrative Therapies as Supportive Care in Patients Treated for Breast Cancer Cite
  Greenlee H, Balneaves LG, Carlson LE, Cohen M, Deng G, Hershman D, et al. Clinical Practice Guidelines on the Use of Integrative Therapies as Supportive Care in Patients Treated for Breast Cancer. JNCI Monographs. Oxford University Press (OUP); 2014; 2014:346-358 10.1093/jncimonographs/lgu041
• Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention Cite
  Grisold W, Cavaletti G, Windebank AJ. Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro-Oncology. Oxford University Press (OUP); 2012; 14:iv45-iv54 10.1093/neuonc/nos203
• Sympathetic and parasympathetic activity in cancer-related fatigue: More evidence for a physiological substrate in cancer survivors Cite
  Fagundes CP, Murray DM, Hwang BS, Gouin J, Thayer JF, Sollers JJ, et al. Sympathetic and parasympathetic activity in cancer-related fatigue: More evidence for a physiological substrate in cancer survivors. Psychoneuroendocrinology. Elsevier BV; 2011; 36:1137-1147 10.1016/j.psyneuen.2011.02.005